Author

Alan W. Partin

Observed names: A Partin, A W Partin, A. Partin, A. W. Partin, A.W. Partin, Alan W Partin

Observed institutions: Merck & Co., Inc., Rahway, NJ, USA (United States), National Institutes of Health, Center for Biologics Evaluation and Research, Johns Hopkins University, Johns Hopkins Medicine, Dianon (United States), National Institute on Aging, National Cancer Institute, Johns Hopkins Hospital

OpenAlex ID: A5111787390

Long-term Results of Radiation Therapy for Prostate Cancer Recurrence Following Radical Prostatectomy

1998 · Jeffrey A. Cadeddu, Alan W. Partin, et al. · The Journal of Urology · 202

Percentage of free prostate-specific antigen in sera predicts aggressiveness of prostate cancer a decade before diagnosis

1997 · H. Ballentine Carter, Alan W. Partin, et al. · Urology · 101

Clinical prospects of long noncoding RNAs as novel biomarkers and therapeutic targets in prostate cancer

2015 · V Mouraviev, B Lee, et al. · Prostate Cancer and Prostatic Diseases · 96

Age, prostate-specific antigen, and digital rectal examination as determinants of the probability of having prostate cancer

2001 · Steven R Potter, Wolfgang Horniger, et al. · Urology · 75

Contemporary identification of patients at high risk of early prostate cancer recurrence after radical retropubic prostatectomy

2001 · William W Roberts, Erik J Bergstralh, et al. · Urology · 75

Nuclear morphometry adds significant prognostic information to stage and grade for renal cell carcinoma

1999 · Michael A Carducci, Steven Piantadosi, et al. · Urology · 44

The role of PSA and percent free PSA for staging and prognosis prediction in clinically localized prostate cancer.

1998 · J Pannek, A W Partin · PubMed · 36

Treatment of early stage prostate cancer: radical prostatectomy.

1994 · P C Walsh, A W Partin · PubMed · 22

The role of free prostate-specific antigen in prostate cancer detection

2000 · Misop Han, Steven R. Potter, et al. · Current Urology Reports · 8

Prostate Cancer, 2nd International consultation on Prostate Cancer

2000 · Chung Lee, G.P. Murphy, et al. · 8

Prostate cancer: Detection, staging, and treatment of localized disease

1999 · Steven R. Potter, Alan W. Partin · Seminars in Roentgenology · 8

PDF

Influence of Age and Prostate-Specific Antigen on the Chance of Curable Prostate Cancer Among Men With Nonpalpable Disease

1999 · H.B. Carter, J.I. Epstein, et al. · The Journal of Urology · 7

The role of prostate needle biopsy in evaluation of chemopreventive agents

2001 · Leonard S Marks, Jonathan I Epstein, et al. · Urology · 4

Untersuchungen zur unterschiedlichen Karzinominzidenz von Prostata und Samenblasen

2002 · J. Pannek, A. W. Partin · Aktuelle Urologie · 3

Predicting cancer on repeat biopsy: Results of a multicenter prospective evaluation of complexed PSA

2003 · G. Bartsch, M. Brawer, et al. · European Urology Supplements · 2

Prostate cancer (PC)-management of 669 cases in Ghana West Africa

2014 · E.D. Yeboah, A.W. Hsing, et al. · African Journal of Urology · 1

Relationship Between Primary Gleason Pattern on Needle Biopsy and Clinicopathological Outcomes Among Men With Gleason 7 Adenocarcinoma of the Prostate

2006 · P.J. Bastian, M.L. Gonzalgo, et al. · European Urology Supplements · 1

Evaluation of Psa for Early Detection of Prostatic Cancer in Men

2003 · Khan, A. Partin · 1

Heredity and Prostate Cancer: A Study of World War II Veteran Twins

1998 · W.F. Page, M.M. Braun, et al. · The Journal of Urology · 1

Minimally Invasive Techniques To Diagnosis And Stage Carcinoma Of The Prostate

2024 · Mark L Gonzalgo, Li-Ming Su, et al. · CRC Press eBooks

Pooled analysis of >1000 patients enrolled in two independent prospective validation studies show consistent performance of a urine exosome gene expression assay to rule-out benign and low-grade prostate cancer at initial biopsy

2019 · M. Noerholm, J. McKiernan, et al. · European Urology Supplements

Resveratrol und neu synthetisierte Resveratrol-Analoga zur Therapie des Prostatakarzinoms

2007 · B. Djavan, S. Marihart, et al. · Der Urologe

128 Serum concentrations of human glandular kallikrein 2 (HK2) but not free PSA, total PSA or %FPSA permit discrimination of pathologically organ-confined (OC) from non-organ confined (NOC), non-palpable (clinical stage T1C) prostate cancer

2004 · A. Haese, V. Vaisanen, et al. · European Urology Supplements

Utilisation of percent free PSA in the total PSA (TPSA) range 2–4 NG/ML does not substantially increase the number of biopsies needed to find significant prostate cancer

2003 · A. Haese, R.T. Dworschack, et al. · European Urology Supplements

Results of a multicenter prospective evaluation of complexed PSA

2002 · G. Bartsch, C.D. Cheli, et al. · European Urology Supplements

Works count: 26

Citation count: 695

H-index: 8

I10-index: 8